Bromfenac eye drop

ApprovedSmall molecule

AAzienda USL Reggio Emilia - IRCCS

Bromfenac eye drop is one of 4 small molecule programs targeting Exfoliation Syndrome. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Exfoliation SyndromeActive, not recruiting

Exfoliation SyndromeApproved

Active, not recruiting

Competition

Competitive Landscape

5 competitors in Exfoliation Syndrome

#DrugCompanyPhaseTrials

Travatan

Novartis

Approved

—2

Timolol Maleate

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Approved

—3

Bromfenac eye drop

AAzienda USL Reggio Emilia - IRCCS

Approved

1 4

AR-12286

AAerie Pharmaceuticals

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Exfoliation Syndrome1 trial

Bromfenac to Reduce Inflammation in Patients With Pseudoexfoliation Syndrome After Cataract Surgery

Completed·AAzienda USL Reggio Emilia - IRCCS·Phase 4·NCT02137161·62 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Bromfenac eye drop. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Bromfenac eye drop compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Bromfenac eye drop. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Azienda USL Reggio Emilia - IRCCS company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: AAzienda USL Reggio Emilia - IRCCS

Bromfenac eye drop

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Exfoliation Syndrome1 trial

References

Drug Info

Quick Facts

Related News